Abstract
Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Current Pharmaceutical Design
Title: Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases
Volume: 17 Issue: 31
Author(s): Daniela M. Arduino, A. Raquel Esteves, Diana F.F. Silva, Diogo Martins-Branco, Daniel Santos, Diana F. Gomes Pimentel and Sandra M. Cardoso
Affiliation:
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Abstract: Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Export Options
About this article
Cite this article as:
M. Arduino Daniela, Raquel Esteves A., F.F. Silva Diana, Martins-Branco Diogo, Santos Daniel, F. Gomes Pimentel Diana and M. Cardoso Sandra, Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072481
DOI https://dx.doi.org/10.2174/138161211798072481 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer’s Disease
Current Alzheimer Research Developing Pharmacotherapies for Cannabis and Cocaine Use Disorders
Current Neuropharmacology The Autism Candidate Gene Neurobeachin Encodes a Scaffolding Protein Implicated in Membrane Trafficking and Signaling
Current Molecular Medicine Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery Resveratrol Improves Cardiovascular Function in DOCA-Salt Hypertensive Rats
Current Pharmaceutical Biotechnology Ethosomes as Novel Vesicular Carrier: An Overview of the Principle, Preparation and its Applications
Current Drug Delivery Electrochemical Biosensor for the Detection of Glycated Albumin
Current Alzheimer Research The Interplay between Cofilin and Phospho-Cofilin: Its Role in Maintaining Blood Brain Barrier Integrity
CNS & Neurological Disorders - Drug Targets Natural Products Combating Neurodegeneration: Parkinson’s Disease
Current Drug Metabolism Antidepressant Like Effects of Alternanthera sessilis and Clerodendrum infortunatum Leaves Extract in Immobility Models
The Natural Products Journal Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants
Current Neuropharmacology Recent Developments in Female Hormonal Contraception
Current Women`s Health Reviews Preface [Hot topic: Autoimmunity (Executive Editors: D. Stahl and W. Sibrowski)]
Current Pharmaceutical Design End-Stage Dementia Spark of Life: Reliability and Validity of the “GATOS” Questionnaire
Current Alzheimer Research Growth Hormone and Insulin-Like Growth Factor-I as an Endocrine Axis in Alzheimers Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action
Protein & Peptide Letters Mammalian Cytosolic Glutathione Transferases
Current Protein & Peptide Science Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design